Weigh the Benefits and Risks

When making your decision, consider both sides of the coin. There may be potential benefits, such as hair regrowth, but you also must be prepared for potential risks.

Possible Benefits:

– You are among the first to receive potential new interventions for a condition

– You make a valuable contribution to research

– You help scientists understand more about alopecia areata and help future individuals

– You are playing a more active role in your healthcare.

– You may have greater access to a team of experts who may be able to provide deeper insight into your alopecia areata

Possible Risks:

– You may experience unexpected side effects from the intervention, ranging from minor or unpleasant side effects to more serious ones requiring medical attention

– The treatment may not be effective for you, or it may not be effective once you finish the trial and go off it

– You may experience discomfort related to the additional medical tests and procedures

– You may have increased expenses relating to the trial that are not covered by the trial team or health insurance. These could include travel costs, housing, childcare, and extra visits to your doctor.

Eligibility Criteria

Every trial study will have eligibility rules that determine whether you are able to participate. These criteria are based on characteristics such as age, gender, stage of the disease, treatment history, and other medical concerns.

Common criteria for alopecia areata clinical trials:

  • The severity of your alopecia areata (% of total hair loss)
  • The cause of hair loss. Whether you have alopecia areata or another type of alopecia such as androgenic alopecia, or scarring alopecia
  • How long you have had alopecia areata
  • Whether you are currently receiving or have recently received treatment for alopecia areata such as immunosuppressants or biologics
  • Whether you are within a defined age group

Clinical Trial Common Terms

Medical interventionPrincipal investigatorEligibility criteriaProtocolInformed consentInstitutional Review Board (IRB)